


10 false beliefs in CCN



37th Vicenza Course
on
AKI & CRRT

May 28-30, 2019

Zaccaria Ricci

Dipartimento Medico Chirurgico
di Cardiologia Pediatrica



Bambino Gesù
OSPEDALE PEDIATRICO



The 10 false beliefs in adult critical care nephrology

Zaccaria Ricci^{1*} , Stefano Romagnoli² and Claudio Ronco^{3,4}

Intensive Care Med 2017


ATN is the main histopathologic finding in AKI	Decreased RBF is the leading cause of AKI during sepsis	Effluent flow equals RRT dose	ATN is an uncommon histopathologic finding in AKI	Septic AKI may occur despite increased RBF	Effluent flow overestimates RRT dose
Extracorporeal blood purification is a "cure" for sepsis	FALSE BELIEFS	Restoration of creatinine levels after AKI implies full recovery	Source control is the "cure" for sepsis	TRUE CONCEPTS	Restoration of creatinine levels is a biased measure of full recovery
High blood flow rates in RRT cause hemodynamic instability		To wean my anuric patient from RRT I could try to force diuresis	Net UF and rapid osmolality decrease may cause hemodynamic instability in RRT		Before attempting to wean my anuric patient from RRT I have to wait for spontaneous diuresis
IJV is the best access for RRT		MAP is the principal hemodynamic target in patients with AKI	Right IJV and femoral veins have similar performances as RRT accesses		Mean and Diastolic PP are reliable hemodynamic targets in patients with AKI
	Fluid challenge is ALWAYS recommended in patients with oliguria			Fluid challenge is ONLY recommended in fluid responsive patients with oliguria and/or hypotension	

FALSE BELIEFS....



1. Decreased RBF is the leading cause of septic AKI
2. Colloids are useful to restore intravascular oncotic pressure
3. Diuretics cause AKI
4. Pre-renal AKI can be always treated by fluid loading
5. Antibiotic dosing should be always reduced during CRRT
6. Anticoagulation of CRRT circuit is not needed during ECMO
7. CRRT Blood flow rate causes hypotension
8. Negative RCTs are not useful
9. Studies on children are NOT useful... on adult patients
10. We like the idea of removing «renal» from all CCN acronyms



1. A decreased RBF is the leading cause of septic AKI



SEPTIC AKI




The presence of a periglomerular circulation offers an anatomical pathway for convective oxygen shunting during sepsis.

Diffusional shunting possibly adds to the development of medullary hypoxia in sepsis. Alternatively, decreased shunting effectiveness may also cause tubular injury through increased ROS production.

Post, KI 2017

Variable responses of regional renal oxygenation and perfusion to vasoactive agents in awake sheep



2. Colloids are useful to restore intravascular oncotic pressure

- Intravenous fluid administration is one of the most common interventions in acute and critical care medicine, but much of the physiological theory on which practice has been based is flawed.
- Intravenous fluids were established in clinical practice and licensed for use without robust investigation of their efficacy or safety, although large, high-quality, investigator-initiated trials have now provided such data.
- **Crystalloid fluids should be used for first-line therapy; in most patients, buffered salt solutions seem to offer benefits over normal saline.**
- **Albumin administration might be beneficial in patients with sepsis, cirrhosis or infections, but is contraindicated in patients with acute traumatic brain injury.**
- **Synthetic colloids, notably hydroxyethyl starch and gelatins, should not be used owing to their unacceptable safety profiles and lack of proven benefits over crystalloids.**


Finfer, Myburgh, Bellomo, Nat Rev Neph 2018



a Classic Starling principle

$$J_V = K[(\rho_c - \rho_i) - \sigma(\pi_c - \pi_i)]$$


Vascular lumen



INTRAVASCULAR EXPANSION RATIO
colloids versus crystalloids
3:1

b Revised Starling principle

$$J_V = (\rho_c - \rho_g) - \sigma(\pi_c - \pi_g)$$




INTRAVASCULAR EXPANSION RATIO
colloids versus crystalloids
1.4:1

The use of plasma or plasma substitutes to achieve a sustained supranormal plasma volume or to reduce tissue oedema is not rational.

Woodcock, BJA 2012

3. Diuretics cause AKI




Source : Pharmacology - An Illustrated Review (Thieme Illustrated Review Series) - Simmons, Mark

DRUG	RBF (%CO)	GFR	TUBULAR Na REABS	Urine flow	DO ₂	O ₂ Ex
furosemide	=	↓	↓	↑	=	↓

10 myths about frusemide

Michael Joannidis^{1*}, Sebastian J. Klein¹ and Marlies Ostermann²




- 1. It does not cause AKI**
- Furosemide and fluids together do not prevent AKI in high-risk patients
- 3. It is not contraindicated in AKI**
- It does not kick-start kidney function
- It may work better if given together with albumin
- Infusion is probably not more effective than boluses
- 7. It does not prevent renal replacement therapy**
- It does not help to wean anuric patients from RRT
- Furosemide-induced diuresis after AKI implies full renal recovery.
- 10. It should not be stopped if serum creatinine is increasing: consider "pseudo worsening renal function"**

4. Pre-renal AKI can be always treated by fluid loading

- The concept of «pre-renal» AKI is unfortunately very diffused
- It generally implies some renal dysfunction due to reduced renal perfusion
- It portends a form of somehow mild and transient oliguria
- Such implication frequently induces to associate «pre-renal» AKI with the need for volemia optimization (fluids)




Starling Curve: fluid responsiveness




Association between systemic hemodynamics and septic acute kidney injury in critically ill patients: a retrospective observational study

Matthieu Legrand^{1,2*}, Claire Dupuis¹, Christelle Simon¹, Etienne Gayat^{1,3}, Joaquim Mateo¹, Anne-Claire Lukaszewicz^{1,2,4} and Didier Payen^{1,2,4}



Renal Compartment Syndrome (post-renal AKI)




TRANSIENT AKI (it does not exclude harm)

PERSISTENT AKI

-FUNCTIONAL AKI

-DAMAGE AKI



5. Antibiotic dosing should be always reduced during CRRT



Dia

How can we ensure effective antibiotic dosing in patients receiving different types of CRRT?

Janattul-Ain Jamal ^a, Bruce A. Howell ^b

^a Burns Trauma and Critical Care Research Center

^b Department of Clinical Social and Administrative Sciences

^c Department of Anaesthesia and Intensive Care,

^d Royal Brisbane and Women's Hospital, Herston

Table 1
Pharmacokinetic parameters of different classes of antibiotics in patients receiving CRRT


Drug/(Reference)	Type of RRT/No. of patients (n)	RRT settings
		Qb (mL/min)
Aminoglycosides		
Amikacin ^a (Akers et al., 2011)	CVVH (n = 12)	NA
Amikacin (Taccone et al., 2011)	CVVHDF (n = 13)	150.0
Amikacin (D'Arcy et al., 2012)	CVVHDF (n = 5)	200.0
Gentamicin (Petejova et al., 2012)	CVVH (n = 7)	200.0



THE SANFORD GUIDE To Antimicrobial Therapy 2019

David N. Gilbert, M.D.
Henry F. Chambers, M.D.
George M. Eliopoulos, M.D.
Michael S. Saag, M.D.
Andrew T. Pavia, M.D.

Douglas Black, Pharm.D.
David O. Freedman, M.D.
Kami Kim, M.D.
Brian S. Schwartz, M.D.



**50 Years
1969-2019**

ase



ients



n A. Roberts ^{a,d,*}

2015

AUC ₀₋₂₄ (mg·h/L)	Cl _{total} (mL/min)	Cl _{CRRT} (mL/min)	S _c
214.8 ± 113.8 ^b	146.7 ± 148.3	NA	NA
NA	88.2 ^{c,d} (7.0–231.0)	NA	NA
NA	58.0 ± 12.3	47.7 ± 6.8	0.8 ± 0.1
NA	61.2 ^b (44.1–107.1)	28.8 ^b (27.9–30.6)	0.8

PK, SC and drug removal during CRRT

DRUG	Renal excret	Free fract (%)	Vd (L Kg ⁻¹)	MW (Da)	SC	RRT Removal
Amikacine	95%	>95%	0.22	586	0.95	S
Amphotericin B	5-10%	10%	4	926	0.35	N
Cefepime	85%	84%	0.3	481	0.72	S
Ceftazidime	60-85%	83%	0.28-0.40	547	0.90	S
Ceftriaxone	30-65%	10%	0.12-0.18	553	0.20	<< other beta-lactams
Ciprofloxacin	50-70%	60-80%	2.5	331	0.70	S
Fluconazole	70%	88%	0.70	306	0.88	↑
Gentamicin	95%	>95%	0.23	478	0.81	S
Imipenem/Cilast	20-70 / 60%	79-87% / 56%	0.22 / 0.24	317/380	0.90/0.75	S
Meropenem	65%	98%	0.35	437	1.0	S
Piperacillin/Tazobactam	75-90 / 65%	70% / 78%	0.25 / 0.21	540/322	0.82	S (Piperacillina > Tazob.)
Teicoplanin	40-60%	10-40%	0.5-1.2	1885	0.05	low
Vancomycin	90-100%	50-90%	0.47-1.1	1448	0.70-0.80	S

Variability of antibiotic concentrations in critically ill patients receiving continuous renal replacement therapy: A multicentre pharmacokinetic study*

Darren M. Roberts, PhD; Jason A. Roberts, PhD; Michael S. Roberts, PhD; Xin Liu, PhD; Priya Nair, FCICM; Louise Cole, PhD; Jeffrey Lipman, MD; Rinaldo Bellomo, MD; on behalf of the RENAL Replacement Therapy Study Investigators

CCM 2012

- Wide variability in trough concentrations: 6.7-fold for meropenem, 3.8-fold for piperacillin, 10.5-fold for tazobactam, 1.9-fold for vancomycin, and 3.9-fold for ciprofloxacin.
- Overall, **15% of dosing intervals did not meet predetermined minimum therapeutic target concentrations**, 40% did not achieve the higher target concentration, and, during **10% of dosing intervals**, **antibiotic concentrations were excessive**.





Optimizing ceftolozane-tazobactam dosage in critically ill patients during continuous venovenous hemodiafiltration

Gerardo Aguilar^{1,2*}, Rafael Ferriols^{2,3}, Sara Martínez-Castro^{1,2}, Carlos Ezquer^{2,3}, Ernesto Pastor^{1,2}, José A. Carbonell^{1,2}, Manuel Alós^{2,3} and David Navarro^{2,4,5}




Table 2 Pharmacokinetic parameters of ceftolozane and tazobactam

Parameter	Ceftolozane		Tazobactam	
	Pre-filter	Post-filter	Pre-filter	Post-filter
Clearance (L/h)	2.1	5.4	6.4	17.4
Volume of distribution (L)	53.9	97.5	108.9	194.2
Half-life (h)	17.9	12.6	11.9	7.8
AUC (h mg/L)	960	373	157	57.6
Maximum concentration (mg/L)	99	53	37	14.5
Minimum concentration (mg/L)	55.9	25.8	11.4	5.1


AUC area under the concentration-time curve



....in ECMO the condition is even worse

- Critically ill patients undergoing high initial doses
- In patients undergoing high initial doses of antibiotics, CRRT are often used to maintain therapeutic levels
- On the other hand, CRRT are often used to maintain therapeutic levels of antibiotics in patients undergoing high initial doses

- Antibiotic, S
- Shekar, CC 2
- meropenem
- Goncales-Pe



ickly

e that
its
requently

ed with
doses

study investigators
ment therapy on

5. Antibiotic dosing might be adjusted during CRRT

1. Therapeutic drug dosing is a mandatory requirement for the future
2. ABT adjustments should consider the renal dose, the utilized membrane, V_d of the patient
3. Side effects should be included in this process
4. Probably ABT dose should be rarely reduced, sometimes increased, tendentially left unchanged



6. Anticoagulation of CRRT circuit is not needed during ECMO

LETTER

Open Access

Intertwining extracorporeal membrane oxygenation and continuous renal replacement therapy: sense or nonsense?



Rita Jacobs, Patrick M Honore* and Herbert D Spapen

See related research by Chen *et al.*, <http://ccforum.com/content/18/6/675>

....” we **strongly argue against the combined use of ECMO and CRRT** within a single circuit. ... A separate CRRT device can perfectly run under a proper dedicated anticoagulation therapy (for example, regional citrate).

This permits avoidance of ECMO-induced” effects such as “ anticoagulant dilution, resulting in less thrombotic events,” and “shear stress, activation of the clotting cascade and release noxious cytokines, which exposes patients to the potential life-threatening effects of hemolysis, disseminated intravascular coagulation and enhanced systemic inflammation”






RESEARCH

Open Access

Combination of extracorporeal membrane oxygenation and continuous renal replacement therapy in critically ill patients: a systematic review


Han Chen¹, Rong-Guo Yu², Ning-Ning Yin¹ and Jian-Xin Zhou^{1*}



Effects of Renal Replacement Therapy in Patients Receiving Extracorporeal Membrane Oxygenation: A Meta-Analysis

Ann Thor Surg 2015

Control mortality




Continuous renal replacement therapy during extracorporeal membrane oxygenation: why, when and how?

2018

Marlies Ostermann^a, Michael Connor Jr^{b,c}, and Kianoush Kashani^d

Table 2. Methods of combining continuous renal replacement therapy with extracorporeal membrane oxygenation

Combination of CRRT and ECMO	Specific type	Advantages	Disadvantages/risks
Integrated approach	In-line haemofilter	Relatively easy to set up Low cost Ability to generate large volumes of ultrafiltrate No need for separate anticoagulation	No pressure monitoring Requires external pump to control ultrafiltration Less precise ultrafiltration Risk of excessive ultrafiltration Limited solute clearance Flow turbulences and risk of haemolysis
	Integration of CRRT device in ECMO circuit	Provision of ultrafiltration and solute clearance Mode of solute clearance not restricted Control of ultrafiltration No need for separate vascular access No need for separate anticoagulation	exposure of CRRT machine to pressures outside the safety range Risk of air entrapment Flow turbulences and risk of haemolysis Risk of thrombus formation on the additional connectors Generation of shunt within ECMO circuit
	Connection of CRRT device to oxygenator	Control of ultrafiltration Pressures maintained within safety range of CRRT device	Potential risk of interfering with oxygenator
Parallel systems	Separate CRRT and ECMO circuits	Provision of ultrafiltration and solute clearance Mode of solute clearance not restricted Precise fluid removal Ability to provide CRRT independent of ECMO No need for separate anticoagulation Option of using separate anticoagulation method to keep CRRT circuit patent No need to involve ECMO team when changing CRRT circuit	Need for separate vascular access Increased difficulty caring for patient with two separate extracorporeal circuits Higher extracorporeal blood volume



NO ANTICOAGULATION IS REASONABLE IN SELECTED CASES

It is not necessary to use full heparin anticoagulation every time the clinicians are concerned about the bleeding risks

- After major surgery and/or epidural cath → no anticoagulation for the first 24-48 hours (or citrate) maybe a safer option
- When another extracorporeal treatment is running (i.e. ECMO) → no additional anticoagulation should be considered
- **Patients already receiving “full” anticoagulation for other reasons** (i.e. warfarin or LMWH for mechanical prosthetic valves)
- A filter life 20-24 hours can be considered a benchmark of adequate patency: if such average duration of a circuit is possible without the administration of any anticoagulation, then the treatment duration can be considered adequate

LESS.... ANTICOAGULATION

HEPARIN DOSING GUIDE

Heparin infusion rate	INR	aPTT	Platelets
10 IU/Kg/h	< 1.5	< 40 s	> 150,000 / mL
5 IU/Kg/h	>1.5 but < 2.5	> 40 s but < 60 s	< 150,000 / mL > 75,000 / mL
No anticoagulation	> 2.5	> 60 s	< 75,000 mL



Kellum JA, Bellomo R, Ronco C - 2015



Continuous Renal Replacement Therapy in Venovenous Extracorporeal Membrane Oxygenation: A Retrospective Study on Regional Citrate Anticoagulation

ASAIO 2019 MARCO GIANI,* VITTORIO SCARAVILLI,† FLAVIA STEFANINI,‡ GABRIELE VALSECCHI,‡ ROBERTO RONA,* GIACOMO GRASSELLI,†§ GIACOMO BELLANI,*‡ ANTONIO M. PESENTI,†§ AND GIUSEPPE FOTI*‡




Table 2. Reason for circuit substitution and circuits lifespan in RCA + UFH and UFH group

	RCA + UFH group	UFH group	p
No. of CRRT circuits	97	53	
CRRT circuit change			<0.001
Clotting	11 (11%)	20 (38%)	
Elective replacement	53 (55%)	12 (23%)	
Others	30 (31%)	19 (36%)	
Unknown	3 (3%)	2(4%)	
CRRT circuit duration, hours	56 [40–72]	50 [31–77]	.67
CRRT circuits used for more than 72 h	19 (19%)	14 (26%)	.32



-Clotting: increase of pressure across the filter (*e.g.* pressure drop > 150 mmHg) or presence of visible clots that required circuit replacement to continue CRRT treatment
 -Unscheduled change: before 72 hours uninterrupted CRRT

- 48 patients CRRT during vv-ECMO in the study period.
- CRRT circuit clotting was 11% in the 22 RCA + UFH group vs. 38% in the 15 UFH group ($p < 0.001$). -11 received both and were exclud-
- No complication with citrate anticoagulation

7. Blood flow rates cause hypotension

- FALSE!
- WHEN THE TREATMENT IS STARTED THE SAME AMOUNT OF BLOOD THAT IS WITHDRAWN FROM THE VEIN IS ALSO REINFUSED (IN THE SAME VEIN)
- VENOUS RETURN IS NOT AFFECTED AT STEADY STATE
- (OTHERWISE V-V ECMO WOULD ALWAYS IMPLY A CATASTROPHIC HEMODYNAMIC INSTABILITY)



7. Blood flow rates cause hypotension

- Priming the extracorporeal circuit with patient's blood **without reinfusing the priming solution** causes a relative hypovolemia.
- Net ultrafiltration rate exceeding the rate of **intravascular refilling** leads to hypovolemia
- **Vasoactive drugs dilution/removal** during ET may decrease serum concentration and therapeutic effect.
- Sudden decrease in blood osmolality during intermittent hemodialysis (**disequilibrium syndrome**) has been shown to be a risk factor for hemodynamic worsening.




8. Negative RCTs are not useful

ORIGINAL ARTICLE

A Comparison of Albumin Resuscitation in the


The SAFE Study



JAMA | Original Investigation | CARING FOR THE CRITICALLY ILL PATIENT

Effect of Targeted Polymyxin B Hemoperfusion on 28-Day Mortality in Patients With Septic Shock and Elevated Endotoxin Level


The EUPHRATES Randomized Clinical Trial



ORIGINAL ARTICLE

Renal-Replacement Insensitive Care Unit

roup



8. Negative RCTs are fundamental

EDITORIAL

Improved survival in critically ill patients:
are large RCTs more useful than personalized
medicine? Yes

Rinaldo Bellomo^{1,4*}, Giovanni Landoni² and Paul Young³



EDITORIAL

Improved survival in critically ill patients:
are large RCTs more useful than personalized
medicine? No

Jean-Louis Vincent*



1. All clinicians are attracted by the belief that their actions are important or even life-saving.

It is easy to accept the idea that a plausible biological hypothesis (i.e. high

unbiased information to guide other

obvious, clinicians cannot really

1) RCT and precision medicine are complementary
2) Negative RCTs allow the possibility of writing EDITORIALS!

- They are endorsed
- Detractors of (negative) RCTs claim that they are essentially wrong comparators: this might be true with
- Also it is stated that most (positive) RCTs only provided evidence of a beneficial treatment
- **Precision medicine is delivered on the basis of the interpretation and integration of many forms of evidence**

9. Studies on children are not useful on adult patients

Studies typically cited on adult meetings including children:

- 1) NGAL in pediatric cardiac surgery, Mishra J, the Lancet 2005
- 2) Children with MODS and CRRT, Goldstein S, KI 2005
- 3) FEAST trial, K Maitland, the NEJM 2011
- 4) AKI definition, KDIGO guidelines, KI 2012
- 5) Fluid overload and outcomes, Alobaidi R, pJAMA 2018



9. Studies on children are useful on adult patients

Other settings where «peds» are certainly going to contribute to the field

- 1) Renal Angina Index (Basu, Lancet Child Adolesc Health 2018)
- 2) ECMO and CRRT (Mallory, Selewsy, Profeta)
- 3) Follow-up of patients recovering

REMEMBER NOT TO OVERLOOK CLINICAL INSIGHTS
DERIVING FROM PEDIATRIC SCIENCE!



10. We like the idea of removing the term «renal» from all CCN acronyms

End Stage **Renal** Disease = End Stage **Kidney** Disease

Chronic **Renal** Failure = Chronic **Kidney** Disease

Acute Renal Failure = Acute Kidney Injury

Renal Replacement Therapy = Extracorporeal **Kidney** Support

Continuous **Renal** Replacement Therapy = Continuous **Kidney** Replacement Therapy

Circuit Clotting = Artificial **Kidney** Failure

Norad**renal**ine = Norepinephrine

Renal Angina Index = **Kidney** Pain Score

RENAL Study = **KIDNEY** Trial



10. We do not like the idea of removing the term «renal» from all CCN acronyms

Villa et al. *Critical Care* (2016) 20:283
DOI 10.1186/s13054-016-1456-5

Critical Care

REVIEW

Open Access



Nomenclature for renal replacement therapy and blood purification techniques in critically ill patients: practical applications

Gianluca Villa^{1,2}, Mauro Neri^{1,3}, Rinaldo Bellomo⁴, Jorge Cerda⁵, A. Raffaele De Gaudio², Silvia De Rosa¹, Francesco Garzotto¹, Patrick M. Honoré⁶, John Kellum⁷, Anna Lorenzin¹, Didier Payen⁸, Zaccaria Ricci⁹, Sara Samoni¹⁰, Jean-Louis Vincent¹¹, Julia Wendon¹², Marta Zaccaria¹, Claudio Ronco¹, on behalf of the Nomenclature Standardization Initiative (NSI) Alliance

Abstract

This article reports the conclusions of the second part of a consensus expert conference on the nomenclature of renal replacement therapy (RRT) techniques currently utilized to manage acute kidney injury and other organ dysfunction syndromes in critically ill patients. A multidisciplinary approach was taken to achieve harmonization of definitions, components, techniques, and operations of the extracorporeal therapies. The article describes the RRT techniques in detail with the relevant technology, procedures, and phases of treatment and key aspects of volume management/fluid balance in critically ill patients. In addition, the article describes recent developments in other extracorporeal therapies, including therapeutic plasma exchange, multiple organ support therapy, liver support, lung support, and blood purification in sepsis. This is a consensus report on nomenclature harmonization in extracorporeal blood purification therapies, such as hemofiltration, plasma exchange, multiple organ support therapies, and blood purification in sepsis.

Keywords: Terminology, Pump, Pressure sensor, CRRT machine, Continuous veno-venous hemodialysis, Continuous veno-venous hemofiltration, Continuous veno-venous hemodiafiltration, High volume hemofiltration, Continuous plasmapheresis coupled with adsorption, Hemoperfusion

Abbreviations: AKI, Acute kidney injury; AVH, Accelerated veno-venous hemofiltration; CPE, Continuous plasma exchange; CPFA, Continuous plasmapheresis coupled with adsorption; CRRT, Continuous renal replacement therapy; CVH, Continuous veno-venous hemofiltration; CVHD, Continuous veno-venous hemodialysis; CVHDF, Continuous veno-venous hemodiafiltration; CWHF, Continuous veno-venous high-flux dialysis; ECMO, Extracorporeal membrane oxygenation; ED, Extended dialysis; EDD, Extended daily dialysis; EDDF, Extended daily dialysis with filtration; FPPA, Fractionated plasma separation and adsorption; HVHF, High-volume hemofiltration; ICU, Intensive care unit; IHD, Intermittent hemodialysis; IHDf, Intermittent hemodiafiltration; IHf, Intermittent hemofiltration; IHDF, Intermittent high-flux dialysis; MARS, Molecular adsorbent recirculating system; MOST, Multiple organ support therapy; PIRRT, Prolonged intermittent renal replacement therapy; PMX, Polymyxin; RRT, Renal replacement therapy; SCUF, Slow continuous ultrafiltration; SLED, Sustained low-efficiency dialysis; SLEDD, Slow low-efficiency extended daily dialysis; SPAD, Single pass albumin dialysis; TMP, Transmembrane pressure; TPE, Therapeutic plasma exchange; VHVHF, Very high-volume hemofiltration

* Correspondence: cronco@goldnet.it

¹Department of Nephrology, Dialysis and Transplantation, International Renal Research Institute of Vicenza, San Bortolo Hospital, Viale Rodolfi 37, 36100 Vicenza, Italy

Full list of author information is available at the end of the article



© 2016 The Author(s). **Open Access** This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<http://creativecommons.org/licenses/by/4.0/>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated.

Neri et al. *Critical Care* (2016) 20:318
DOI 10.1186/s13054-016-1489-9

Critical Care

REVIEW

Open Access



Nomenclature for renal replacement therapy in acute kidney injury: basic principles

Mauro Neri^{1,2}, Gianluca Villa^{1,3}, Francesco Garzotto¹, Sean Bagshaw⁴, Rinaldo Bellomo⁵, Jorge Cerda⁶, Fiorenza Ferrari¹, Silvia Guggia¹, Michael Joannidis⁷, John Kellum⁸, Jeong Chul Kim⁹, Ravindra L. Mehta¹⁰, Zaccaria Ricci¹¹, Alberto Trevisani¹², Silvio Marafon¹², William R. Clark¹³, Jean-Louis Vincent¹⁴, Claudio Ronco^{1*} and on behalf of the Nomenclature Standardization Initiative (NSI) alliance

Abstract

This article reports the conclusions of a consensus expert conference on the basic principles and nomenclature of renal replacement therapy (RRT) currently utilized to manage acute kidney injury (AKI). This multidisciplinary consensus conference discusses common definitions, components, techniques, and operations of the machines and platforms used to deliver extracorporeal therapies, utilizing a “machine-centric” rather than a “patient-centric” approach. We provide a detailed description of the performance characteristics of membranes, filters, transmembrane transport of solutes and fluid, flows, and methods of measurement of delivered treatment, focusing on continuous renal replacement therapies (CRRT) which are utilized in the management of critically ill patients with AKI. This is a consensus report on nomenclature harmonization for principles of extracorporeal renal replacement therapies. Devices and operations are classified and defined in detail to serve as guidelines for future use of terminology in papers and research.

Keywords: Terminology, Diffusion, Convection, Ultrafiltration, Transmembrane pressure, CRRT membranes, CRRT modalities, Dose, CRRT efficiency, Clearance

Background

The management of critically ill patients with acute kidney injury (AKI) requiring renal replacement therapy (RRT) demands a multidisciplinary approach. In spite of previous efforts at harmonization, the terminology used to describe the different aspects and modalities of RRT is often confusing. A consensus conference on RRT terminology was organized to develop common definitions for the components, techniques, and operation of the machines and platforms used for acute extracorporeal therapies.

In this article, we report the conclusions of the consensus group on the basic principles underlying RRT technologies and the application of those principles to patient care, using “machine-centric” rather than “patient-centric” terminology. We provide a detailed description of the

performance characteristics of membranes and filters, solute and fluid transport mechanisms across membranes, flow rate parameters, and methods of treatment evaluation, focusing on the continuous RRT (CRRT) used in the treatment of critically ill patients.

Methodology

A conference was organized in Vicenza, Italy, to gather experts in CRRT and members of CRRT manufacturing companies to establish consensus on technical terminology and definitions relevant to basic principles of CRRT and related technology [1]. The conference provided the background for a modified Delphi consensus methodology as previously utilized for the Acute Disease Quality Initiative consensus sessions [2]. Prior to the conference, participants screened the literature of the last 25 years and previous taxonomy efforts [3–5]. Keywords included “continuous renal replacement therapy”, “dialysis”, “hemofiltration”, “convection”, “diffusion”, “ultrafiltration”, “dose”, “blood purification”, “renal support”, “multiorgan dysfunction”, together with the

* Correspondence: cronco@goldnet.it

¹Department of Nephrology, Dialysis and Transplantation, International Renal Research Institute of Vicenza, San Bortolo Hospital, Viale Rodolfi 37, Vicenza 36100, Italy

Full list of author information is available at the end of the article



© 2016 The Author(s). **Open Access** This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<http://creativecommons.org/licenses/by/4.0/>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated.

...LESS FALSE BELIEFS

1. Alteration in intra-RBF may be on the reasons of septic AKI
2. Colloids do not restore intravascular oncotic pressure
3. Diuretics can be indicated in congestive AKI
4. Pre-renal AKI is a flawed paradigm
5. Antibiotic dosing should be adjusted (rarely reduced) during CRRT
6. Several options can be considered for anticoagulation of CRRT circuit during ECMO
7. CRRT Blood flow rates are not the causes of HIRRT
8. Negative RCTs are fundamental
9. Studies on children are VERY useful... for adult patients
10. We like the idea of leaving «renal» on all CCN acronyms